Your browser is no longer supported. Please, upgrade your browser.
Abeona Therapeutics Inc.
Index- P/E- EPS (ttm)-1.04 Insider Own0.90% Shs Outstand93.77M Perf Week0.41%
Market Cap243.40M Forward P/E- EPS next Y-0.65 Insider Trans-65.77% Shs Float84.39M Perf Month18.63%
Income-84.80M PEG- EPS next Q-0.11 Inst Own40.10% Short Float3.50% Perf Quarter74.10%
Sales7.00M P/S34.77 EPS this Y-27.10% Inst Trans5.68% Short Ratio0.72 Perf Half Y3.86%
Book/sh1.23 P/B1.97 EPS next Y22.90% ROA-47.00% Target Price- Perf Year-26.89%
Cash/sh0.96 P/C2.51 EPS next 5Y- ROE-62.00% 52W Range0.99 - 4.03 Perf YTD54.14%
Dividend- P/FCF- EPS past 5Y37.00% ROI- 52W High-40.02% Beta1.60
Dividend %- Quick Ratio2.70 Sales past 5Y- Gross Margin- 52W Low144.57% ATR0.38
Employees88 Current Ratio2.70 Sales Q/Q- Oper. Margin- RSI (14)50.70 Volatility17.43% 15.79%
OptionableYes Debt/Eq0.02 EPS Q/Q77.90% Profit Margin- Rel Volume3.42 Prev Close2.49
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume4.10M Price2.42
Recom1.70 SMA20-4.91% SMA5015.52% SMA20010.30% Volume14,030,558 Change-2.81%
Nov-11-20Upgrade Cantor Fitzgerald Neutral → Overweight $4
Sep-18-20Initiated B. Riley FBR Buy $5
Feb-10-20Initiated SVB Leerink Outperform $6
Dec-10-19Resumed Cantor Fitzgerald Neutral $2 → $4
Aug-15-19Downgrade Maxim Group Buy → Hold
Aug-12-19Downgrade Cantor Fitzgerald Overweight → Neutral $29 → $2
Jul-26-19Downgrade Mizuho Buy → Neutral $17 → $4
Jun-27-19Initiated Mizuho Buy
Oct-12-18Initiated Mizuho Buy $17
Jun-05-18Initiated Seaport Global Securities Buy $29
Nov-08-17Initiated SunTrust Buy $26
Oct-16-17Reiterated H.C. Wainwright Buy $20 → $30
Oct-11-17Reiterated Cantor Fitzgerald Overweight $21 → $34
Oct-10-17Initiated Citigroup Buy $32
Oct-05-17Reiterated Maxim Group Buy $17 → $35
Sep-15-17Initiated RBC Capital Mkts Outperform $23
Jul-18-17Reiterated Maxim Group Buy $14 → $17
Jun-22-17Resumed Jefferies Buy $22
Jan-06-17Initiated Jefferies Buy
Sep-29-16Reiterated Maxim Group Buy $8 → $14
Feb-25-21 11:33AM  
Feb-22-21 07:30AM  
Feb-12-21 11:36AM  
Feb-02-21 07:30AM  
Jan-25-21 07:30AM  
Jan-12-21 08:50AM  
Dec-21-20 12:20PM  
Dec-14-20 09:44PM  
Dec-01-20 10:06AM  
Nov-27-20 08:25AM  
Nov-24-20 03:10PM  
Nov-18-20 11:24AM  
Nov-17-20 01:16PM  
Nov-12-20 05:21AM  
Nov-09-20 05:55PM  
Oct-27-20 06:30AM  
Oct-14-20 10:58PM  
Oct-06-20 04:01PM  
Sep-28-20 09:27AM  
Sep-18-20 11:08AM  
Sep-08-20 04:05PM  
Sep-01-20 06:29AM  
Aug-17-20 07:00AM  
Aug-10-20 04:01PM  
Aug-04-20 11:36AM  
Jul-10-20 07:30AM  
Jul-09-20 09:10AM  
Jul-08-20 07:30AM  
Jul-03-20 07:48AM  
Jun-23-20 11:59AM  
Jun-18-20 07:30AM  
Jun-17-20 07:30AM  
Jun-08-20 09:11AM  
May-28-20 11:30AM  
May-08-20 12:58PM  
May-07-20 01:59PM  
May-06-20 04:14PM  
Apr-29-20 11:08AM  
Apr-21-20 04:04PM  
Apr-20-20 08:43AM  
Apr-17-20 07:00AM  
Apr-06-20 09:16AM  
Apr-05-20 04:12AM  
Mar-27-20 06:19PM  
Mar-23-20 12:00PM  
Mar-17-20 07:30AM  
Mar-16-20 04:20PM  
Feb-26-20 08:00AM  
Feb-21-20 08:45AM  
Feb-12-20 02:15PM  
Jan-21-20 08:00AM  
Jan-15-20 09:33AM  
Jan-13-20 09:00AM  
Jan-02-20 12:12PM  
Dec-31-19 12:30PM  
Dec-27-19 08:30PM  
Dec-24-19 02:20PM  
Dec-20-19 06:20PM  
Dec-19-19 05:20PM  
Dec-18-19 03:59PM  
Dec-17-19 02:25PM  
Dec-16-19 07:10PM  
Dec-15-19 10:00AM  
Dec-14-19 09:36AM  
Dec-13-19 04:30PM  
Dec-12-19 01:30PM  
Dec-11-19 05:17PM  
Dec-09-19 05:45PM  
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. Abeona Therapeutics Inc. has a license agreement with REGENXBIO Inc. for the development and commercialization of gene therapies for the treatment of MPS IIIA, MPS IIIB, CLN1 disease, and CLN3 disease. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mann Paul ElliotDirectorFeb 19Option Exercise1.2845,56658,32445,566Feb 23 04:14 PM
Wider ToddDirectorFeb 19Sale2.39251,625601,05725,000Feb 23 04:05 PM
Mann Paul ElliotDirectorFeb 19Sale2.3845,566108,5020Feb 23 04:14 PM
Wider ToddDirectorFeb 18Option Exercise1.281,3451,722277,970Feb 19 04:05 PM
Wider ToddDirectorFeb 18Sale2.431,3453,273276,625Feb 19 04:05 PM
Wider ToddDirectorFeb 17Option Exercise1.28320,000409,600596,625Feb 19 04:05 PM
Wider ToddDirectorFeb 17Sale2.34320,000749,792276,625Feb 19 04:05 PM
Mann Paul ElliotDirectorFeb 17Sale2.34132,664310,1680Feb 19 04:05 PM
SCO CAPITAL PARTNERS LLCDirectorFeb 16Sale2.97120,000356,80811,239,292Feb 18 04:05 PM
SCO CAPITAL PARTNERS LLCDirectorFeb 08Sale3.01240,000722,83211,359,292Feb 10 07:42 PM
SCO CAPITAL PARTNERS LLCDirectorJan 19Sale2.08207,117431,21811,599,292Jan 19 06:48 PM
SCO CAPITAL PARTNERS LLCDirectorJan 15Sale2.0281,283164,08611,806,409Jan 19 06:48 PM
SCO CAPITAL PARTNERS LLCDirectorJan 14Sale2.0031,60063,21311,887,692Jan 19 06:48 PM
Wider ToddDirectorJan 04Sale1.5433,87652,064276,625Jan 05 07:09 PM
Mann Paul ElliotDirectorJan 04Sale1.5430,48846,891132,664Jan 05 07:07 PM
Mann Paul ElliotDirectorDec 18Sale1.5917,07927,099772,907Dec 21 06:16 PM
Wider ToddDirectorDec 02Sale1.4933,87650,546920,256Dec 02 04:26 PM
Mann Paul ElliotDirectorDec 02Sale1.4930,48845,369789,986Dec 02 04:25 PM
Wider ToddDirectorNov 23Sale1.3317,96923,981954,132Nov 24 06:46 PM
Mann Paul ElliotDirectorNov 02Sale1.0430,48831,589820,474Nov 06 04:54 PM
Wider ToddDirectorNov 02Sale1.0433,87635,106972,101Nov 06 04:55 PM
SCO CAPITAL PARTNERS LLCDirectorSep 15Sale2.001,9893,98111,919,292Sep 17 04:05 PM
SCO CAPITAL PARTNERS LLCDirectorSep 11Sale2.014,6009,24411,921,281Sep 14 08:35 PM
SCO CAPITAL PARTNERS LLCDirectorSep 10Sale2.0873,411152,48211,925,881Sep 14 08:35 PM
SCO CAPITAL PARTNERS LLC10% OwnerAug 17Sale2.8580,000228,31211,999,292Aug 19 04:05 PM
CARR EDWARDChief Accounting OfficerMar 19Sale1.816,44611,66713,554Mar 20 04:14 PM